CN103582491B - 2型糖尿病患者中低血糖症的预防 - Google Patents
2型糖尿病患者中低血糖症的预防 Download PDFInfo
- Publication number
- CN103582491B CN103582491B CN201280026545.9A CN201280026545A CN103582491B CN 103582491 B CN103582491 B CN 103582491B CN 201280026545 A CN201280026545 A CN 201280026545A CN 103582491 B CN103582491 B CN 103582491B
- Authority
- CN
- China
- Prior art keywords
- treatment
- patient
- hypoglycemia
- purposes
- lixisenatide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11160270.2 | 2011-03-29 | ||
EP11160270 | 2011-03-29 | ||
PCT/EP2012/055660 WO2012130955A1 (en) | 2011-03-29 | 2012-03-29 | Prevention of hypoglycaemia in diabetes mellitus type 2 patients |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103582491A CN103582491A (zh) | 2014-02-12 |
CN103582491B true CN103582491B (zh) | 2016-12-07 |
Family
ID=44504331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280026545.9A Active CN103582491B (zh) | 2011-03-29 | 2012-03-29 | 2型糖尿病患者中低血糖症的预防 |
Country Status (20)
Country | Link |
---|---|
US (2) | US20120277147A1 (es) |
EP (1) | EP2691109B1 (es) |
JP (1) | JP6410600B2 (es) |
KR (1) | KR20140033030A (es) |
CN (1) | CN103582491B (es) |
AU (1) | AU2012234180B2 (es) |
BR (1) | BR112013024973B1 (es) |
CA (1) | CA2830811A1 (es) |
CY (1) | CY1116799T1 (es) |
DK (1) | DK2691109T3 (es) |
ES (1) | ES2549955T3 (es) |
HK (1) | HK1192725A1 (es) |
HR (1) | HRP20151087T1 (es) |
HU (1) | HUE025716T2 (es) |
MX (1) | MX336657B (es) |
PL (1) | PL2691109T3 (es) |
PT (1) | PT2691109E (es) |
RU (1) | RU2583134C2 (es) |
SI (1) | SI2691109T1 (es) |
WO (1) | WO2012130955A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010043566A2 (de) | 2008-10-17 | 2010-04-22 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem insulin und einem glp-1-agonisten |
US9707176B2 (en) | 2009-11-13 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
ES2855146T3 (es) | 2009-11-13 | 2021-09-23 | Sanofi Aventis Deutschland | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
PT2611458T (pt) | 2010-08-30 | 2016-12-16 | Sanofi Aventis Deutschland | Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
PT2750699E (pt) | 2011-08-29 | 2015-11-03 | Sanofi Aventis Deutschland | Acelerómetro pendular |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
SG11201604706TA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin aspart |
CN112957455A (zh) | 2014-01-09 | 2021-06-15 | 赛诺菲 | 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂 |
WO2015104311A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
WO2020112253A2 (en) * | 2018-10-16 | 2020-06-04 | The Board Of Regents Of The University Of Oklahoma | Uses of glucagon-like peptide-1 receptor agonists for treating trauma-induced hearing loss |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1413582A (zh) * | 2002-11-29 | 2003-04-30 | 贵州圣济堂制药有限公司 | 盐酸二甲双胍肠溶片及其制备方法 |
WO2007001150A2 (en) * | 2005-06-27 | 2007-01-04 | Jae-Kwan Hwang | Method for preventing and treating conditions mediated by ppar using macelignan |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
SK287810B6 (sk) * | 1999-11-03 | 2011-10-04 | Bristol-Myers Squibb Company | Farmaceutický prostriedok obsahujúci nízkodávkovú kombináciu metformínu a glyburidu |
PT1928499E (pt) * | 2005-09-20 | 2011-09-09 | Novartis Ag | Utilização de um inibidor da dpp-iv para reduzir eventos hipoglicémicos |
WO2010043566A2 (de) * | 2008-10-17 | 2010-04-22 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem insulin und einem glp-1-agonisten |
-
2012
- 2012-03-28 US US13/432,811 patent/US20120277147A1/en not_active Abandoned
- 2012-03-29 BR BR112013024973-0A patent/BR112013024973B1/pt active IP Right Grant
- 2012-03-29 RU RU2013148014/15A patent/RU2583134C2/ru active
- 2012-03-29 HU HUE12712106A patent/HUE025716T2/en unknown
- 2012-03-29 DK DK12712106.9T patent/DK2691109T3/en active
- 2012-03-29 SI SI201230333T patent/SI2691109T1/sl unknown
- 2012-03-29 PL PL12712106T patent/PL2691109T3/pl unknown
- 2012-03-29 KR KR1020137028491A patent/KR20140033030A/ko active Search and Examination
- 2012-03-29 AU AU2012234180A patent/AU2012234180B2/en active Active
- 2012-03-29 EP EP12712106.9A patent/EP2691109B1/en not_active Revoked
- 2012-03-29 MX MX2013011174A patent/MX336657B/es unknown
- 2012-03-29 CN CN201280026545.9A patent/CN103582491B/zh active Active
- 2012-03-29 CA CA2830811A patent/CA2830811A1/en active Pending
- 2012-03-29 JP JP2014501623A patent/JP6410600B2/ja active Active
- 2012-03-29 WO PCT/EP2012/055660 patent/WO2012130955A1/en active Application Filing
- 2012-03-29 ES ES12712106.9T patent/ES2549955T3/es active Active
- 2012-03-29 PT PT127121069T patent/PT2691109E/pt unknown
-
2014
- 2014-06-23 HK HK14105960.9A patent/HK1192725A1/xx not_active IP Right Cessation
-
2015
- 2015-10-14 HR HRP20151087TT patent/HRP20151087T1/hr unknown
- 2015-10-15 CY CY20151100924T patent/CY1116799T1/el unknown
-
2017
- 2017-01-20 US US15/411,557 patent/US20180000902A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1413582A (zh) * | 2002-11-29 | 2003-04-30 | 贵州圣济堂制药有限公司 | 盐酸二甲双胍肠溶片及其制备方法 |
WO2007001150A2 (en) * | 2005-06-27 | 2007-01-04 | Jae-Kwan Hwang | Method for preventing and treating conditions mediated by ppar using macelignan |
Non-Patent Citations (1)
Title |
---|
Lixisenatide,a novel GLP-1 receptor agonist for the treatment of type2 diabetes mellitus;Christensen et al;《I Drugs》;20090831;第12卷(第8期);摘要,第505页右栏倒数第1-2段,第506页左栏倒数第1-3段,第506页右栏,第507页左栏,第508页左栏,第509页右栏倒数第1段,第510页左栏第1段 * |
Also Published As
Publication number | Publication date |
---|---|
RU2013148014A (ru) | 2015-05-10 |
ES2549955T3 (es) | 2015-11-03 |
SI2691109T1 (sl) | 2015-11-30 |
CN103582491A (zh) | 2014-02-12 |
CY1116799T1 (el) | 2017-03-15 |
JP6410600B2 (ja) | 2018-10-24 |
PT2691109E (pt) | 2015-10-30 |
WO2012130955A1 (en) | 2012-10-04 |
HUE025716T2 (en) | 2016-04-28 |
CA2830811A1 (en) | 2012-10-04 |
HK1192725A1 (en) | 2014-08-29 |
US20120277147A1 (en) | 2012-11-01 |
DK2691109T3 (en) | 2015-10-19 |
PL2691109T3 (pl) | 2015-12-31 |
MX336657B (es) | 2016-01-27 |
US20180000902A1 (en) | 2018-01-04 |
MX2013011174A (es) | 2013-11-01 |
AU2012234180B2 (en) | 2017-02-16 |
EP2691109B1 (en) | 2015-07-15 |
KR20140033030A (ko) | 2014-03-17 |
JP2014514289A (ja) | 2014-06-19 |
HRP20151087T1 (hr) | 2015-11-20 |
AU2012234180A1 (en) | 2013-10-17 |
EP2691109A1 (en) | 2014-02-05 |
BR112013024973A2 (pt) | 2016-08-30 |
BR112013024973B1 (pt) | 2022-06-07 |
RU2583134C2 (ru) | 2016-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103582491B (zh) | 2型糖尿病患者中低血糖症的预防 | |
Fonseca | Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus | |
CN107375909A (zh) | 在2型糖尿病患者中预防低血糖症 | |
EP1928499B1 (en) | Use of a dpp-iv inhibitor to reduce hypoglycemic events | |
Richter et al. | Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus | |
AU2012257850B2 (en) | Lixisenatide as add-on therapy to basal insulin in type 2 diabetes | |
CN107496907A (zh) | 诱导ii型糖尿病患者体重减轻或/和防止ii型糖尿病患者体重增加的药物组合产品 | |
CN104066441A (zh) | 2型糖尿病的治疗方案 | |
Thompson et al. | Pramlintide: A human amylin analogue reduced postprandial plasma glucose, insulin, and C‐peptide concentrations in patients with type 2 diabetes | |
Tack et al. | Randomized forced titration to different doses of Technosphere® insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes | |
CN108079281A (zh) | 用于2型糖尿病患者中的血糖控制的药物组合 | |
CN107693782A (zh) | 用于治疗2型糖尿病患者的利西拉来和二甲双胍 | |
CN105473155A (zh) | 甘精胰岛素/利西拉来固定比率配制剂 | |
Mahmood et al. | Prescription pattern analysis of antidiabetic drugs in diabetes mellitus and associated comorbidities | |
K Myers et al. | Death by insulin: Management of self-harm and suicide in diabetes management | |
CN107405386A (zh) | 使用利西拉来治疗儿科2型糖尿病患者 | |
Haak | Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia | |
CA2865823A1 (en) | Basal insulin therapy | |
Ghosal et al. | Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: a retrospective real world comparative data from India | |
Young | Clinical studies | |
Elgzyri | Basic management of diabetes mellitus: practical guidelines | |
Kabadi et al. | Improved metabolic control in insulin-dependent diabetes mellitus with insulin and tolazamide | |
Dzida et al. | A prospective evaluation of the effectiveness and safety of Insulin Glargine 100 U/mL (Gla-100) in adults with diabetes mellitus in Poland. The LARE observational study | |
Kolap et al. | Diabetes mellitus A Case Study | |
SEE et al. | The Effect of Glimepiride on Glycemic Control |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |